


| Key | % Net Assets |
|---|---|
| 4.4% | |
| 4.2% | |
| 4.1% | |
| 3.9% | |
| 83.4% |
| Name | % Net Assets |
|---|---|
| BP | 4.4% |
| HSBC | 4.2% |
| Citigroup FRN 10/8/2011 | 4.1% |
| Royal Bank of Scotland | 3.9% |
| Barclays | 3.8% |
| BT | 3.6% |
| HBOS FRN 17/12/2009 | 3.3% |
| New York Life FRN 8/9/2009 | 3.3% |
| Santander Intnl Debt FRN 27/1/2011 | 3.2% |
| GlaxoSmithKline | 2.9% |
No asset data available.
| Date | 20-Aug-2025 |
|---|---|
| NAV | 317.48p |
| Currency | GBP |
| Change | 0.59p |
| % | 0.19% |
| YTD change | 33.55p |
| YTD % | 11.82% |
| Fund Inception | 31/10/2006 |
|---|---|
| Fund Manager | Michael Fraikin |
| TER | 0.70 (31-Dec-2013) |
| Minimum Investment | |
|---|---|
| Initial | n/a |
| Additional | n/a |
| Savings | n/a |
| Charges | |
|---|---|
| Initial | n/a |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| No risk data available. | |
You are here: research